Contact this trialFirst, we need to learn more about you.
PRMT5 Inhibitor
TNG456 + Abemaciclib for Solid Tumors
Recruiting1 awardPhase 1 & 2
Fairfax, Virginia
This trial is testing a new drug called TNG456, both by itself and in combination with abemaciclib, in patients with advanced solid tumors that have a specific genetic mutation. The trial has
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service